Company intelligence / Profile preview

AIMOTO

Santa Barbara, California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Aimoto is a biotechnology company specializing in generative artificial intelligence for drug discovery and molecular design. The company leverages advanced deep learning models to design novel small molecules with optimized pharmacological properties. By integrating AI with high-throughput screening and computational chemistry, Aimoto aims to accelerate the development of new therapeutics across various disease areas. The platform is designed to explore vast chemical spaces more efficiently than traditional methods, potentially reducing the time and cost of early-stage drug discovery.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Drug Discovery Services

Beyond the preview

Go deeper on AIMOTO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIMOTO.

Explore the full profile